Mr. Daniel brings in more than 27 years of experience in Sales & Marketing functions in the Pharmaceutical sector to the senior team of IBPL. In his earlier assignments, Mr. Daniel played a key role in establishing Oncology, Cardiology, Gynaecology and Diabetology business and successfully launched new products and new divisions in the respective segments. Mr. Daniel is a Post Graduate in Marketing & Business Administration.
At IBPL, Mr Daniel is in-charge of Marketing, Sales & Business Development activities for indigenously developed biotechnology products, which includes therapeutic recombinant proteins Neukine (rHu G-CSF), Erykine & Epofit (rHu EPO), Intalfa (rHu IFN Alfa-2b) and Neupeg (Peg rHu G-CSF) in the domestic market and some international markets. Intas Biopharmaceuticals Limited (IBPL) is the only company in the state of Gujarat with an impressive track record of launching four indigenously developed biotech products in as many years. Additionally, Mr Daniel is also in-charge of Marketing & Sales division of Oncology products, which comprises of product range catering to Solid Tumour, Haematology Malignancies & Supportive Therapies.
IBPL’s competitive strength is centred on extensive experience of its management and is in the forefront of new technological, quality and regulatory trends. On the Marketing & Business Development front, currently, IBPL’s products are under registration in more than 60 countries. Domestically, the company has strategic arrangements to penetrate the highly competitive market. IBPL has also entered into several supply and marketing agreements with reputed international companies in regulated and semi-regulated markets of Europe, Asia-Pacific, Middle East, Russia & CIS, South and Central America and Africa.
About Intas Biopharmaceuticals
Intas Biopharmaceuticals Limited (IBPL) has fully integrated biopharmaceutical operations at Ahmedabad, Gujarat. Since the launch of biotechnology operations in May 2000, Research & Development (R&D) and manufacturing of biopharmaceutical products with a special focus on Oncology (Cancer) are major thrust areas for the company. IBPL has carved a niche in the biopharmaceutical operations with the one–of-its-kind of manufacturing facility in India certified by European Agency for the Evaluation of Medicinal Products (EMEA) for one of its lead product. In terms of quality standards, the facility complies with strict international Good Manufacturing Practice regulations and conforms to guidelines laid down by World Health Organization (WHO).
